Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis.
COVID-2019
MRI
SARS-CoV-2
cardiac
myocarditis
outcome
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
12 04 2022
12 04 2022
Historique:
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
14
4
2022
Statut:
ppublish
Résumé
Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19-associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe. A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19-associated AM. AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19-associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia ( AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.
Sections du résumé
BACKGROUND
Acute myocarditis (AM) is thought to be a rare cardiovascular complication of COVID-19, although minimal data are available beyond case reports. We aim to report the prevalence, baseline characteristics, in-hospital management, and outcomes for patients with COVID-19-associated AM on the basis of a retrospective cohort from 23 hospitals in the United States and Europe.
METHODS
A total of 112 patients with suspected AM from 56 963 hospitalized patients with COVID-19 were evaluated between February 1, 2020, and April 30, 2021. Inclusion criteria were hospitalization for COVID-19 and a diagnosis of AM on the basis of endomyocardial biopsy or increased troponin level plus typical signs of AM on cardiac magnetic resonance imaging. We identified 97 patients with possible AM, and among them, 54 patients with definite/probable AM supported by endomyocardial biopsy in 17 (31.5%) patients or magnetic resonance imaging in 50 (92.6%). We analyzed patient characteristics, treatments, and outcomes among all COVID-19-associated AM.
RESULTS
AM prevalence among hospitalized patients with COVID-19 was 2.4 per 1000 hospitalizations considering definite/probable and 4.1 per 1000 considering also possible AM. The median age of definite/probable cases was 38 years, and 38.9% were female. On admission, chest pain and dyspnea were the most frequent symptoms (55.5% and 53.7%, respectively). Thirty-one cases (57.4%) occurred in the absence of COVID-19-associated pneumonia. Twenty-one (38.9%) had a fulminant presentation requiring inotropic support or temporary mechanical circulatory support. The composite of in-hospital mortality or temporary mechanical circulatory support occurred in 20.4%. At 120 days, estimated mortality was 6.6%, 15.1% in patients with associated pneumonia versus 0% in patients without pneumonia (
CONCLUSIONS
AM occurrence is estimated between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19. The majority of AM occurs in the absence of pneumonia and is often complicated by hemodynamic instability. AM is a rare complication in patients hospitalized for COVID-19, with an outcome that differs on the basis of the presence of concomitant pneumonia.
Identifiants
pubmed: 35404682
doi: 10.1161/CIRCULATIONAHA.121.056817
pmc: PMC8989611
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1123-1139Références
Circulation. 2021 Feb 9;143(6):553-565
pubmed: 33186055
J Mol Cell Cardiol. 2020 Oct;147:74-87
pubmed: 32827510
Circulation. 2021 Aug 10;144(6):506-508
pubmed: 34133884
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176
pubmed: 30545455
Catheter Cardiovasc Interv. 2019 Jul 1;94(1):29-37
pubmed: 31104355
Circulation. 2021 Mar 9;143(10):1031-1042
pubmed: 33480806
JAMA Cardiol. 2021 Jul 1;6(7):745-752
pubmed: 33662103
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
Circulation. 2021 Aug 10;144(6):471-484
pubmed: 34281357
Circ Heart Fail. 2020 Nov;13(11):e007405
pubmed: 33176455
Mod Pathol. 2021 Jul;34(7):1345-1357
pubmed: 33727695
JAMA Cardiol. 2020 Jul 1;5(7):819-824
pubmed: 32219357
J Cardiovasc Magn Reson. 2017 Oct 9;19(1):75
pubmed: 28992817
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Cardiovasc Med (Hagerstown). 2020 Jul;21(7):529-531
pubmed: 32487867
Lancet Respir Med. 2021 Apr;9(4):e32-e34
pubmed: 33617781
Circ Res. 2020 May 8;126(10):1443-1455
pubmed: 32252591
JAMA Cardiol. 2021 Sep 1;6(9):1078-1087
pubmed: 34042947
Cardiovasc Res. 2020 May 1;116(6):1097-1100
pubmed: 32227090
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87
pubmed: 33308262
J Am Coll Cardiol. 2016 Apr 19;67(15):1800-1811
pubmed: 27081020
Circulation. 2020 Jun 9;141(23):1903-1914
pubmed: 32297796
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
J Am Coll Cardiol. 2019 Jul 23;74(3):299-311
pubmed: 31319912
Circulation. 2020 Feb 11;141(6):e69-e92
pubmed: 31902242
Heart Fail Rev. 2022 Jan;27(1):251-261
pubmed: 33761041
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Eur J Heart Fail. 2016 Dec;18(12):1430-1441
pubmed: 27748022
J Card Fail. 2019 Jan;25(1):60-63
pubmed: 30103022
Cardiovasc Pathol. 2021 Jan - Feb;50:107300
pubmed: 33132119
Circulation. 2021 Jul 27;144(4):256-266
pubmed: 33866822
Eur Heart J. 2020 Oct 14;41(39):3827-3835
pubmed: 32968776
J Am Heart Assoc. 2020 Apr 7;9(7):e016219
pubmed: 32233755
Circulation. 2017 Aug 8;136(6):529-545
pubmed: 28576783
Eur Heart J. 2021 May 14;42(19):1866-1878
pubmed: 33596594
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Chest. 2021 Feb;159(2):657-662
pubmed: 32910974
Circulation. 2019 Jul 02;140(2):80-91
pubmed: 31390169
Circ Heart Fail. 2020 Oct;13(10):e007485
pubmed: 32844662
Circulation. 2016 Dec 6;134(23):e579-e646
pubmed: 27832612
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
J Am Coll Cardiol. 2010 Mar 2;55(9):928-9
pubmed: 20153131
Eur J Heart Fail. 2021 Jul;23(7):1242-1245
pubmed: 34036693
Nat Rev Cardiol. 2021 Mar;18(3):169-193
pubmed: 33046850
Circulation. 2018 Sep 11;138(11):1088-1099
pubmed: 29764898
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
J Am Coll Cardiol. 2021 May 4;77(17):2260-2262
pubmed: 33926664
Circulation. 2007 Nov 6;116(19):2216-33
pubmed: 17959655